Ipamorelin may be blended with CJC-1295 DAC, a modified version of growth hormone-releasing hormone (GHRH) with an extended half-life
For questions, please feel free to Contact Us
Back Unger, RH, Ketterer, H Dupr, J, Eisentraut, I (1967) 'The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs', Journal Clinical Investigation , 46/4, 63045

Jenn and I discuss: How natural GLP-1 production can decline with age Why under-fueling is still the primary issue for many athletes Different types and forms of GLP-1 meds Who should (and shouldn't) consider these medications Potential risks of GLP-1 use, including muscle loss, bone density loss, and GI distress Potential benefits to inflammation, autoimmune conditions, gut health, and mood Nutrition and supplement strategies when appetite is lower Dosing and microdosing for therapeutic use, not just weight loss Why some athletes cycle on and off these meds, or may only need them for a short period of time Why Jenn takes most clients off GLP-1s during race training The stigma around GLP-1 use among athletes Jenn's own story: early menopause, a cardiovascular family history, and how a short course changed her running Why solid diet and lifestyle habits must always come first I hope this episode helps you better understand the complexities of GLP-1 medications in endurance athletes, and why there's rarely a simple yes-or-no answer to the questions we explore together

These were mild to moderate and did not lead to treatment discontinuation
Herczeg, V